PAP
RLAY icon

Persistent Asset Partners’s Relay Therapeutics RLAY Stock Holding History

Persistent Asset Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-303
Closed -$9.85K – 227
2025
Q1 		$9.85K Hold
303
– – 0.01% 158
2024
Q4 		$24.2K Buy
+303
New +$1.65K 0.02% 124

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Persistent Asset Partners's RLAY Position: Q2 2026 in Review

Persistent Asset Partners increased its Relay Therapeutics (RLAY) stake by 332% in Q2 2026, buying an estimated $789K and bringing the position to 70,693 shares worth $1.32M. The position accounts for 0.39% of the portfolio, ranked #54.

Persistent Asset Partners first reported a position in RLAY in Q4 2024 and has held it in 6 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Persistent Asset Partners held 70,693 shares of Relay Therapeutics worth $1.32M as of Q2 2026.
  • Persistent Asset Partners bought 54,335 Relay Therapeutics shares in Q2 2026, an estimated $789K.
  • Relay Therapeutics made up 0.39% of Persistent Asset Partners's portfolio in Q2 2026, its #54 holding.
  • Persistent Asset Partners first reported a position in Relay Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.